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Parkinson’s disease (PD) is a common neurodegenerative disease. Motor symptoms of rigidity, tremor, and bradykinesia and 
non-motor symptoms like the cognitive deficit, autonomic dysfunction, dementia, anxiety and depression all contribute to 
morbidity. Emerging shreds of evidence suggest the role of BDNF (Val66Met) polymorphism in PD risk and associated 
cognitive deficit. Hence, the current study is aimed to investigate the role of BDNF Val66Met in the risk of PD development 
and associated cognitive abnormalities. A total of 269 PD cases and 271 healthy, age, ethnicity and gender matched 
controls were recruited in the study. Genomic DNA was isolated, amplified and SNP was identified using the RFLP method 
and validated by Sanger’s sequencing. There was a significant association of BDNF Val66Met with PD risk in  
both Dominant and recessive models (GG vs GA+AA: OR: 1.47, CI: 1.04-2.09, P =0.03, GG+GA vs AA: OR: 2.32,  
CI: 1.07-5.00, P =0.02). The main nonmotor symptom i.e. cognitive impairment was significantly associated with the 
variant genotype of BDNF Val66Met Polymorphism (GG vs GA+AA: OR: 1.47, CI: 1.04-2.09, P =0.03, GG+GA vs  
AA: OR: 2.32, CI: 1.07-5.00, P =0.02).We found a significant association of variant genotype with disease severity, the 
activity of daily living as assessed by S & E score as it was found to better with wild genotype and a significant decrease in 
quality of life with homozygous mutant genotype. We did not find significant differences in disease duration, absolute 
levodopa response among the genotypes. Our results implicate BDNF Val66Met polymorphism is associated with the risk 
of PD, cognitive impairment, poor quality of life and greater disease severity in PD.  
Keywords: BDNF polymorphism, Bradykinesia, Cognitive impairment, Dementia, MoCA, Parkinson’s disease 
Parkinson’s disease (PD) is one of the common 
neurodegenerative diseases, presenting with tremors, 
rigidity, bradykinesia, abnormal posture and gait as 
the cardinal features. The non-motor symptoms  
of PD include olfactory dysfunction, cognitive 
impairment, sleep disorder, pain, depression, anxiety, 
autonomic nervous dysfunction etc., which can  
occur during PD or earlier than motor symptoms, 
totally reducing the quality-of-life1. Among the  
non-motor symptoms, cognitive impairment 
represents an important non-motor characteristic of 
the disease. In a study, the development of cognition 
was shown to be 8.5% in a year, which reached 47.4% 
in 6 years duration of the disease2. 
The pathophysiology of PD-related cognitive 
impairment is still unknown. It is believed that 
environmental and genetic factors contribute to the 
development of this symptom3 and it is reported to be 
related to many mechanisms, such as reactive 
microgliosis, altered protein handling, oxidative 
stress, and mitochondrial dysfunction4. Among the 
environmental factors, aging seems to be an essential 
contributor to impaired cognition5. From the literature 
and neuropathological findings, cognitive impairment 
of PD was shown to be correlated with the number of 
cortical Lewy bodies, neurofibrillary tangles, senile 
plaques (Alzheimer’s disease- related pathological 
changes) and cerebrovascular lesions. At present, the 
specific susceptibility genes for cognitive impairment 
of PD are still unknown.  
The Brain Derived Neurotrophic Factor is a 
protein encoded by the BDNF gene, found on 
chromosome 116,7. BDNF has several known single 
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nucleotide polymorphisms (SNP) of which Val66Met 
is most frequently studied polymorphism in 
neuropathological conditions. A common SNP - 
Val66Met (rs6265)8 is a point mutation in the coding 
sequence, where guanine to adenine substitution at 
position 196, results in a valine to methionine i.e., an 
amino acid switch at 66th codon and is unique to 
humans8,9. This substitution interferes with normal 
translation of BDNF mRNA and normal intracellular 
trafficking8. This mutation results in a reduction of 
hippocampal tissue which is reported in a high 
number of individuals suffering from learning and 
memory disorders9, anxiety disorders10, and 
neurodegenerative diseases such as Alzheimer's and 
Parkinson's11. The ‘A’ allele is associated with 
abnormal packaging of the precursor of BDNF and 
decreased mature BDNF production in cells12,13. 
In recent studies, investigation of genes involved 
in neuroplasticity in association with cognitive 
functions showed interesting results14. Results from 
the studies have shown that brain-derived 
neurotrophic factor (BDNF), can significantly 
enhance the dopaminergic neurons’ tolerance against 
the acidic environment, and is significantly down-
regulated in the ventral substantia nigra of PD 
patients15. Emerging evidences have indicated the 
possible role of BDNF protein on cognition in 
normal and neuropathological conditions. It is 
evident from the literature that BDNF promotes 
survival, differentiation, and maintenance of 
neuronal cells and also acts as a mediator in long-
term potentiation (LTP), which is involved with 
memory formation in the hippocampus16. The role of 
genetic polymorphisms of the BDNF gene in 
cognitive impairment associated with PD is still 
unclear. BDNF G196A (Val66Met, rs6265) 
polymorphism is one of the most frequently studied 
BDNF gene polymorphisms. A study in hippocampal 
mice cells shows the functional polymorphism of 
BDNF (Val66Met) impair BDNFsecretion17,9. 
Val66Met polymorphism has been reported to be 
involved in impaired episodic memory function16,8. 
The Causative and curative roles of BDNF 
(Val66Met) and its mechanism in cognitive 
impairment in PD have been described18. In a study, 
the functional Val66Met BDNF polymorphism was 
not associated with PD susceptibility19, but it is 
associated with cognitive impairment20 and planning 
ability in PD21. In a study, it was shown that 
proBDNF initiate the heteromer formation of sertolin 
and neurotrophic receptors such as TrkA or TrkB , 
thereby triggers the neuronal cell death22. However, 
in other studies, BDNF Val66Met polymorphism 
was found to have no association with cognitive 
functioning in PD23,24. Because of conflicting and 
inconclusive findings20,25-29, the present study is 
aimed to investigate the role of BDNF Val66Met 
with PD susceptibility and its association with 
cognitive impairment in south Indian PD patients. 
 
Materials and methods 
 
Study subjects  
The current study was conducted in 306 PD 
patients visiting outpatient unit of Department of 
Neurology, Nizam’s Institute of Medical Sciences, 
Hyderabad, Telangana. A total of 271 healthy age-and 
gender matched controls were recruited in the study 
and of 306 PD patients genotyping was done in 269 
subjects, who had accepted for genetic analysis. All 
the patients were recruited, based on UK Parkinson’s 
disease society brain bank clinical criteria (except the 
presence of family history which is not considered 
exclusion criteria). Patients who had secondary 
Parkinson’s disease (drug induced), atypical 
Parkinsonian syndromes and other neurological 
disorders were excluded from the study. Baseline 
characteristics such as gender, age, height, weight, 
body mass index, disease duration, age at onset of all 
of the patients were obtained using a self-designed 
questionnaire and medical records. Clinical 
parameters like disease severity by Hoehn and Yahr 
(H & Y) Scale, Motor performance by Unified 
Parkinson’s disease rating scale (UPDRS)- part III 
scores in “OFF” (12 h without dopaminergic 
medication) and “ON” (best response state after 
levodopa challenge) states, cognition by MoCA 
(Montreal Cognitive Assessment), activity of daily 
living by S & E and Quality of life by PDQ39 Scoring 
were assessed in each patient. This study was 
approved by the Institutional Ethics Committee (IEC) 
of Nizam’s Institute of Medical Sciences (NIMS), 
(EC/NIMS/18/2017), Hyderabad, India. The informed 
consent was obtained from all the subjects. 
 
Sample collection 
Five milliliter blood samples were collected from 
both cases and controls. Blood was subjected to 
centrifugation at 3000 rpm for 10 min for the 
separation of plasma and serum at 4C temperature 
and stored at −20C for further analysis. Genomic 
DNA was extracted from whole blood using the 
standard phenol–chloroform extraction protocol. 
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Genotyping of BDNF Val66Met Polymorphism 
Genotyping of BDNF Val66Met polymorphism 
was determined by using standard PCR method30 and 
the primers used were i) BDNF forward: 5- AGA 
AGAGGAGGCTCCAAAGG -3 and ii) BDNF 
reverse: 5- AAACATCCGAGGACAAGG TG-3 . 
Ten microliters volume was used for each PCR 
reaction, containing 2 picomole/μl of each primer,  
5 µL of Takara Emerald Amp GT polymerase chain 
reaction (PCR) master mix, together with 3–4 μL of  
50 ng/µL genomic DNA using Eppendorf master 
cycler. PCR conditions for the amplification were as 
follows: initial denaturation at 94°C for 5 min, 
followed by 40 cycles of 30 sec at 94°C, 15 sec at 
54.8°C and 45 sec at 72°C for an extension, and a 
final extension of 10 min at 72°C. The amplified  
PCR fragments were run on 3% agarose gel and were 
visualized using an ultraviolet transilluminator for 
genotyping. The PCR amplification results in 249-bp 
length amplicon which are subjected to restriction 
digestion with NlaIII enzyme (New England Biolabs, 
MA, USA) at 37°C for 120 min. Fragments of 203 bp 
and 46 bp correspond to the wild G/G genotype, 
whereas, 126 bp, 77 bp, 46 bp fragments correspond 
for mutant A/A genotype and 203 bp, 126 bp, 77 bp, 
46 bp fragments correspond for the G/A genotype. 
These were separated by 3% agarose gel 
electrophoresis and were visualized using an 
ultraviolet transilluminator for genotyping. Genotype 
was crosschecked in 10% of the samples by 
Sanger’s sequencing and found 100% concordance. 
 
Clinical assessment 
These were the assessments performed Hoehn and 
Yahr (H&Y): PD severity was determined by 
modified H & Y staging. Stage (0-5 severity). MoCA: 
Montreal Cognitive Assessment (Range: 0-30,  
≥26 normal, <26 impaired cognition), S & E: Schwab 
and England activities of daily living scale (100-0% 
disability), PDQ 39: Parkinson’s disease 
questionnaire (higher the score worse will be the 
quality of life). 
UPDRS III: Unified Parkinson’s disease rating 
scale part III clinician-scored monitored motor 
evaluation in ‘on’ and ‘off’ states, aLR: absolute 
Levodopa response measured as change in  
UPDRS III (OFF-ON). aLR%: Mean Levodopa 
response measured as a percentage change in  
UPDRS III (OFF-ON)/OFF*100), Tremor dominant, 
a kinetic rigidity and mixed type PD patients were 
divided.31 
Statistical analysis 
Genotype frequencies were tested for the deviation 
from Hardy–Weinberg equilibrium using chi square 
(χ2) test32. Simple gene counting was performed to 
find out the allele and genotype frequency distributions 
between the cases and controls. The test of associations 
was performed by Fisher's exact two-tailed test using  
the online tool Vassar Stats Calculator 
(www.faculty.vassar.edu/lowry/VassarStats.html). 
GraphPad Prism Software 5.0 (San Diego, USA)  
was used for generating bar graphs. Statistical 
significance for all the tests was considered if a  
two-tailed P value is < 0.05. 
 
Results 
 
Demographic characteristics of PD patients 
The demographic characteristics of cases and 
controls are shown in Table 1. There were 210 male 
patients and 96 female patients. Among the PD cases, 
there were 18 familial PD cases and 288 had Sporadic 
PD. Data were further segregated into early onset 
PD (EOPD) (<50 years) and late-onset PD (LOPD) 
(>50 years) and results show that 15 and 3 familial 
PD cases, 132 and 156 sporadic PD cases were in 
EOPD and LOPD groups, respectively. The mean age 
of cases was 56.92 ± 10.97 years and controls were 
56.12 ± 10.59 years, respectively. The mean age of 
EOPD patients was 48.44 ± 8.29 years whereas, 64.76 
± 6.35 years in LOPD patients which is statistically 
significant (P =<0.0001).The disease duration of PD 
was 7.08 ± 4.38 years. The disease duration was 
significantly high in patients with EOPD, 8.52 ± 4.93 
years as compared to LOPD group, 5.75 ± 3.29 years 
(P =<0.0001).  
The distribution of symptoms of PD i.e., right side 
onset was reported in 47.4% cases, whereas left side 
onset was observed in 42.5% cases and 10.1% 
reported bilateral onset of PD. Further the data was 
segregated among EOPD and LOPD groups and 
founds 46.9% and 47.8% cases reported right side 
onset, 44.9%, 40.3% patients with left side onset and 
8.2%, 11.9% cases of bilateral onset, respectively. 
Symmetric onset of PD was observed in 10.5% of 
patients whereas 89.5% of patients reported 
asymmetric onset of PD among which 8.2% and 
11.9% cases of symmetric onset, 91.8% and 88.1% 
cases of asymmetric onset were reported each in 
EOPD and LOPD groups. Cardinal features of PD 
such as tremors were dominant in 16% cases among 
which 17% cases in EOPD group and 15.1% cases in 
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LOPD group, whereas akinetic rigidity was dominant 
in 72.9% cases out of which 74% in EOPD group, 
71.7% in LOPD group, and mixed symptoms were 
seen in 11.1% cases out of which 9% in EOPD group, 
13.2% in LOPD group, respectively. Major diagnostic  
criteria for PD UPDRS III motor examination 
revealed, the mean OFF score as 52.96 ± 11.65, which 
was distributed significantly high 55 ± 12.07 with the 
EOPD group (P =0.0031) and 51.07 ± 1095 with 
LOPD group, whereas mean ON score 15.39 ± 6.76, 
where 15.27 ± 6.34 in EOPD group and 15.49 ± 7.14 
in LOPD group was observed. The mean change in 
Levodopa response (aLR) was 37.56 ± 9.10, which 
was found significantly (P =<0.0001) less 39.72 ± 
9.20 with LOPD compared to 35.57 ± 8.57 EOPD 
group. The mean of aLR was calculated by aLR% and 
it was found to be significantly reduced with LOPD 
group (P =0.034).  
The disease severity score of PD i.e., H & Y stage 
was 2.68 ± 0.76 whereas 2.69 ± 0.76 was observed 
with EOPD group and 2.68 ± 0.76 with LOPD group, 
respectively. The measure of cognitive impairment 
i.e., MOCA score was 27.59 ± 2.77 where the EOPD 
group showed 27.45 ± 2.29 in EOPD group and 27.64 
± 2.84 with the LOPD group. The S & E score was 
67.54 ± 16.07, with 67.19 ± 16.62 EOPD group and 
67.86 ± 15.60 with LOPD group was observed. 
Quality of life questioner i.e., PDQ 39 was 36.85 ± 
29.82 where 67.24 ± 28.86 and 60.72 ± 30.43 was 
observed with EOPD and LOPD groups, respectively 
and was found significantly (P =0.05) decreased 
quality of life with LOPD group (Tables 1 & 2). There 
was no significant difference between male and female 
patients with all the above parameters. 
 
Association of BDNF Val66Met polymorphisms with PD 
The distribution of genotype frequency of BDNF 
Val66Met polymorphism was in accordance with 
Hardy- Weinberg Equilibrium in both cases  
and controls (P >0.05). Allele and genotype 
frequencies of BDNF Val66Met polymorphism are 
given in (Table 3). The genotype frequencies of 
BDNF Val66Met polymorphism shows higher 
frequency of homozygous wild G/G genotype with 
57.6% genotypic distribution in cases and 66.8% in 
controls, followed by heterozygous G/A genotype 
with 34.2% genotype distribution in cases and 29.5% 
in controls, and homozygous mutant A/A genotype 
with 8.2% in cases and 3.7% in healthy controls 
group, respectively. The genotype distribution 
between cases and controls showed a significant 
difference in both dominant and recessive models 
(GG vs GA+AA: OR: 1.47, CI: 1.04-2.09, P =0.03; 
GG+GA vs AA: OR: 2.32, CI: 1.07-7-5.00, P = 0.02). 
The allelic distribution of wild ‘G’ allele was 74.72% 
in cases and 81.55 %in controls, whereas ‘A’allele 
frequency was 25.28% in cases and 18.45% in healthy 
control group, respectively which was found 
significant between cases and controls (OR: 1.49, CI: 
1.11-2.00, P =0.008) (Table 3). 
 
Association of Age, age at onset and disease duration with 
variant genotypes  
The age and age at onset were compared between 
the wild and variant genotypes, where we could  
not find a significant difference between wild, 
heterozygous and mutant variants (Age: G/G: 56.68 ± 
0.87 years, G/A: 58.62 ± 1.18 years, A/A: 55.15 ± 
Table 1 — Demographic data in PD cases and controls 
Parameters PD Cases Control P value 
Age (Years) 56.92 ± 10.97 56.12 ± 10.59 0.42 
Male 210 (68.6%) 180 (66.6%)  
Female 96 (31.4%) 90 (29.4%)  
Age at onset (Years) 49.83 ±11.73 - - 
Disease duration (Years) 7.08 ± 4.38 - - 
EOPD 147 (48.0%) - - 
LOPD 159 (52.0%) - - 
Familial PD 18 (5.9%) - - 
Sporadic PD 288 (94.1%) - - 
Consanguinity 80 (2.6%) - - 
Right side onset 145 (47.4%) - - 
Left side onset 130 (42.5%) - - 
Bi lateral onset 31 (10.1%) - - 
Symmetric onset 32 (10.5%) - - 
Asymmetric onset 274 (89.5%) - - 
Tremor Dominant PD 49 (16.0%) - - 
Akinetic Rigidity 
dominant PD 
223 (72.9%) - - 
Mixed symptom PD 34 (11.1%) - - 
UPDRS 3 OFF 52.96 ± 11.65 - - 
UPDRS 3 ON 15.39 ± 6.76 - - 
aLR 37.56 ± 9.10 - - 
aLR% 71.32 ± 9.87 - - 
H & Y 2.68 ± 0.76 - - 
S & E 67.54 ± 16.07 - - 
MoCA 27.59 ± 2.77 - - 
aLR, absolute Levodopa response; aLR%, absolute Levodopa 
response percentage; EOPD, Early onset Parkinson’s disease; PDQ 
39, Parkinson’s disease questionnaire; LOPD, Late onset 
Parkinson’s disease; MoCA, Montreal cognitive assessment; PD, 
Parkinson’s disease; PDQ 39, Parkinson’s disease questionnaire; S & 
E, Schwab and England score; UPDRS III, Unified Parkinson’s 
disease rating scale; *P Value ≤0.05 considered as significant. 
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1.975 years), Age at onset: G/G: 49.26 ± 0.94 years, 
G/A: 51.54 ± 1.300 years, A/A: 48.55 ± 1.95 years). 
The mean disease duration was compared and there was 
no significant difference between wild, heterozygous 
and mutant variants: G/G: 7.41 ± 0.37 years, G/A: 7.07 
± 0.45 years, A/A: 6.63 ± 0.55 years, respectively. 
 
Association of UPDRS III Off and On scores with variant 
genotypes 
The mean OFF and ON scores were compared 
between the variant genotypes, and found to have no 
significant difference between the wild, heterozygous 
and mutant variants, UPDRS III OFF score: G/G: 
52.98 ± 0.94, G/A: 53.23 ± 1.18, A/A: 57.85 ± 1.99 
whereas UPDRS III ON score: G/G: 15.05 ± 0.50, 
G/A: 15.96 ± 0.88, A/A: 19.79 ± 1.14. 
 
Association of aLR and aLR % with variant genotypes 
aLR and aLR% are the Levodopa response patterns 
observed in PD patients after medication. There was 
no significant difference between the different 
genotype variants with aLR: G/G: 37.94 ± 0.77, G/A: 
37.27 ± 0.92, A/A: 38.06 ± 1.37 and with aLR%: 
G/G: 71.75 ± 0.77, G/A: 70.71 ± 1.25, A/A: 69.85 ± 
1.45 in wild, heterozygous and mutant variants, 
respectively. 
 
Association of BDNF Val66Met with H & Y stage 
The disease severity score i.e., modified H & Y 
stage when compared between the genotypes of 
BDNF Val66Met polymorphism, and found a 
significantly high disease severity with the variant 
genotype (A/A: 2.90 ± 0.14, P =0.01) compared to 
wild type (G/G: 2.57 ± 0.05). When the wild and 
heterozygous genotypes were compared, the 
heterozygous genotype carrying the variant allele 
(G/A: 2.90 ± 0.08, P =0.008) showed significantly 
greater disease severity compared to wild genotype 
(G/G: 2.57 ± 0.05) (Table 4). 
 
Association of BDNF Val66Met with S & E score 
The Schwab and England ADL (Activities of Daily 
Living) scale is a method of assessing the capabilities 
of people suffering from impaired mobility where the 
scale assesses the difficulties patients have 
completing daily activities. The S& E score was 
Table 2 — Demographic data distribution in EOPD and LOPD 
groups 
Parameters EOPD (N=147) LOPD (N=159) P Value 
Age (Years) 48.44 ±8.29 64.76 ± 6.35 <0.0001* 
Age at onset 
(Years) 
39.90 ± 7.23 59.00 ± 6.40 <0.0001* 
Disease Duration 
(Years) 
8.52 ± 4.93 5.75 ± 3.29 <0.0001* 
Male 96 (65.3%) 114 (71.7%) - 
Female 51 (34.7%) 45 (28.3%)  
Familial PD 15 (10.2%) 3 (1.9%)  
Sporadic PD 132 (89.8%) 156 (98.1%)  
Consanguinity 31 (21.0%) 12 (7.5%)  
RT side onset 69 (46.9%) 76 (47.8%)  
Lt side onset 66 (44.9%) 64 (40.3%)  
Bi lateral onset 12 (8.2%) 19 (11.9%)  
Symmetric onset 12 (8.2%) 19 (11.9%)  
Asymmetric onset 135 (91.8%) 140 (88.1%)  
Tremor Dominant 25 (17.0%) 24 (15.1%)  
Akinetic Rigidity 
dominant 
109 (74.0%) 114 (71.7%)  
Mixed symptom 13 (9.0%) 21 (13.2%)  
UPDRS 3 OFF 55 12.07 51.07 ± 10.95 0.0031* 
UPDRS 3 ON 15.27 ± 6.34 15.49 ± 7.14 0.7765 
aLR 39.72 ± 9.20 35.57 ± 8.57 <0.0001* 
aLR% 72.56± 9.23 70.18 ± 10.32 0.0348* 
H & Y 2.69 ± 0.76 2.68 ± 0.76 0.9085 
S & E 67.19 ± 16.62 67.86 ± 15.60 0.6903 
MOCA 27.45 ± 2.29 27.64 ± 2.84 0.522 
PDQ 39 67.24 ± 28.86 60.72 ± 30.43 0.05* 
aLR, absolute Levodopa response; aLR%, absolute Levodopa 
response percentage; EOPD, Early onset Parkinson’s disease; 
PDQ 39, Parkinson’s disease questionnaire; LOPD, Late onset 
Parkinson’s disease; MoCA, Montreal cognitive assessment; PD, 
Parkinson’s disease; PDQ 39, Parkinson’s disease questionnaire; 
S & E, Schwab and England score; UPDRS III, Unified 
Parkinson’s disease rating scale; *P Value ≤0.05 considered as 
significant. 
Table 3 — Frequency distribution of BDNF Val66Met 
polymorphism 
Genotype Cases Frequency 
(N=269) 
Controls Frequency 
(N=271) 
GG 155 (57.6%) 181 (66.8%) 
GA 92 (34.2%) 80 (29.5%) 
AA 22 (8.2%) 10 (3.7%) 
G 401 (74.72%) 442 (81.55%) 
A 135 (25.28%) 100 (18.45) 
Model OR (CI at 95% 
confidence) 
P value 
Dominant  
(GG vs GA+AA) 
1.47 (1.04-2.09) 0.03* 
Recessive  
(GG+GA vs AA) 
2.32 (1.07-5.00) 0.02* 
Allelic distribution   
G vs A 1.49 (1.11-2.00) 0.008* 
OR, odds ratio; CI, Class interval; GG, wild type; GA, 
Heterozygous; AA, mutant genotype; G, wild type allele; A, 
mutant allele; frequency expressed in %, *P Value ≤0.05 
considered as significant. 
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found better with wild (69.47 ± 1.21) genotype 
compared to mutant genotypes (65.76 ± 2.85), but 
could not reach significance. When wild genotype 
(69.47 ± 1.21) was compared to heterozygous (64.20 
± 1.89), we found a significant (P =0.01) decrease in 
S & E score with heterozygous genotype carrying 
variant allele (Table 4). 
 
Association of BDNF Val66Met with Tremor dominant, 
Akinetic rigidity, and mixed symptom PD group 
Higher number of patients were showing patients 
showing akinetic rigidity dominance (71.7%) 
compared to tremor dominant (16.3%) and mixed 
symptom (11.9%). Genotype wise these symptoms 
were analysed, where 20.6% were tremor dominant, 
67.7% akinetic rigidity dominant and 11.6% cases 
were with mixed symptom in GG genotype, 14.13% 
tremor dominant, 77.17 % akinetic rigidity and 8.7% 
were with mixed symptoms in GA genotype. 77.27% 
were akinetic rigidity, 22.72% were with mixed 
symptoms in AA genotype but we could not find a 
single case with tremor predominant with AA 
genotype (Table 5). 
 
Association of BDNF Val66Met with MoCA 
Montreal Cognitive Assessment (MoCA) score is 
used as a screening assessment for detecting cognitive 
impairment. When MoCA was compared between 
wild (G/G: 28.13 ± 0.15) and mutant (A/A: 25.48 ± 
0.40, P =<0.0001) genotypes, cognition was 
significantly more impaired with variant genotype.  
A significant difference in MoCA score was also 
observed with heterozygous genotype (G/A: 27.64 ± 
0.25) compared to homozygous variant genotype 
(A/A: 25.48 ± 0.40, P =<0.0001) (Table 6). Cognitive 
impairment is more prevalent among akinetic rigid 
subgroup of PD patients. When the patients of PD 
were segregated into Tremor dominant (TD), Akinetic 
Rigidity (AR) and Mixed symptom (MD) groups, the 
impact of variant genotype on cognitive impairment 
persisted in the subgroups. Cognition was 
significantly worse in patients with mutant genotypes 
in AR group (G/G: 28.04 ± 0.60, A/A: 25.68 ± 0.44,  
P <0.0001) and MD group (G/G: 27.61 ± 0.60, A/A: 
24.40 ± 0.92, P =0.01) and none of the mutant group 
had tremor predominant PD (Table 7). 
 
Association of BDNF Val66Met with PDQ39 
The 39-item Parkinson’s disease Questionnaire 
(PDQ-39) is widely used to assess the quality of life 
of PD patients. When PDQ-39 was compared between 
wild (59.68 ± 2.19) and variant (74.36 ± 4.68) 
genotypes, we noted a significant decrease in the 
quality of life of PD patients with homozygous 
mutant genotype (Table 6). 
Within the tremor dominant group genotype, wise 
PDQ39 was compared where no significant difference 
was found between wild and heterozygous variants. 
When genotype wise PDQ 39 was compared within 
the akinetic rigidity dominant group, significantly 
reduced quality (75.11 ± 5.44) of life was found with 
heterozygous (P = 0.03) compared to (62.33 ± 2.78) 
wild genotype, similarly significantly reduced quality 
Table 4 — Association of BDNF Val66Met polymorphism with  
H & Y and S & E score distribution 
Genotype H & Y Mean ± SD (N) P Value 
GG vs GA 2.57 ± 0.05 (155) vs  
2.90 ± 0.08 (92) 
0.0008* 
GG vs AA 2.57 ± 0.05 (155) vs  
2.90 ± 0.14 (22) 
0.0158* 
GA vs AA 2.90 ± 0.08 (92) vs  
2.90 ± 0.14 (22) 
0.9917 
 S & E Mean ± SD (N)  
GG vs GA 69.47 ± 1.21 (155) vs  
64.20 ± 1.89 (92) 
0.0158* 
GG vs AA 69.47 ± 1.21 (155) vs  
65.76 ± 2.85 (22) 
0.2093 
GA vs AA 64.20 ± 1.89 (92) vs  
65.76 ± 2.85 (22) 
0.6547 
GG, wild type; GA, Heterozygous; AA, mutant genotype; H & Y, 
modified Hoehn and Yahr scale; S & E, Schab England score; 
*P Value ≤0.05 considered as significant. 
Table 5 — Genotype wise Frequency distribution of Tremor 
dominant, Akinetic rigidity and mixed symptom PD group 
Genotype Tremor 
Dominant PD 
Akinetic Rigidity 
dominant PD 
Mixed 
symptom PD 
GG 32 (20.6%) 105 (67.7%) 18 (11.6%) 
GA 13(14.13%) 71 (77.17%) 8 (8.70 %) 
AA - 17 (77.27%) 5 (22.72%) 
GG, wild type; GA, Heterozygous; AA, mutant genotype; 
PD= Parkinson’s disease *P Value ≤0.05 considered as significant. 
 
Table 6 — Association BDNF Val66Met polymorphism with 
MOCA and PDQ 39 
Genotype MoCA Mean ± SD (N) P Value 
GG vs GA 28.13 ± 0.15 (155) vs 27.64 ± 0.25 (92) 0.087 
GG vs AA 28.13 ± 0.15 (155) vs 25.48 ± 0.40 (22) < 0.0001* 
GA vs AA 27.64 ± 0.25 (92) vs 25.48 ± 0.40 (22) < 0.0001* 
 PDQ 39 Mean ± SD (N)  
GG vs GA 59.68 ± 2.19 (155) vs 65.52 ± 3.21 (92) 0.5058 
GG vs AA 59.68 ± 2.19 (155) vs 74.36 ± 4.68 (22) 0.0054* 
GA vs AA 65.52 ± 3.21 (92) vs 74.36 ± 4.68 (22) 0.1343 
GG, wild type; GA, Heterozygous; AA, mutant genotype; MoCA, 
Montreal Cognitive assessment; PDQ 39, Parkinson’s disease 
questionnaire; *P Value ≤0.05 considered as significant. 
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of life (75.46 ± 5.00) found with mutant genotype  
(P = 0.02) compared to (75.46 ± 5.00) wild genotype. 
Whereas the significantly poor quality of life (79.60 ± 
7.28) with mutant variant (P =0.05) compared to 
heterozygous variant (54.00 ± 7.95) within mixed 
symptom group (Table 8). 
 
Discussion 
Parkinson’s disease although, more common in 
people >65 years, can affect the younger people 
too.33,34 PD is multifactorial in origin, resulting in 
progressive degeneration of the dopaminergic neurons 
of the nigrostriatal pathway, neuro-inflammation, 
Lewy bodies’ deposits and the damage of the neural 
circuits that predominantly control movement, along 
with other functions.35-37 The origin of the motor and 
non-motor complications of PD can be due to several 
genetic alterations that have been described, including 
α-synuclein, SNCA, PINK 1, DJ-1, LRRK2, 
ATP13A2, PLA2G6, FBX07, VPS35, and BDNF 
genes.38,39 Independent of the etiologic origin, patients 
with PD can develop various non-motor symptoms 
which can cause major morbidity and cognitive 
dysfunction is a major contributor. BDNF gene 
mutations are reported to be associated with such non-
motor complications in PD.  
BDNF gene encodes the protein Brain Derived 
Neurotrophic Factor, involved in neuroplasticity14 
which promotes survival, differentiation, and 
maintenance of neuronal cells. To the best of our 
knowledge, there are no studies available to date 
exploring the role of BDNF Val66Met polymorphism 
in South Indian PD subjects. Hence, the present study 
was carried out to explore the association of BDNF 
Val66Met variants with PD risk and cognitive 
impairment. We found a significant increase of “A 
allele” frequency in PD patients (25.28%) compared 
to the controls (18.45%) and established a significant 
association of BDNF Val66Met “A/A genotype” as 
well as “A allele” in PD. Worldwide, the distribution 
of alleles have been reported, with the highest 
prevalence of Val/Val allele (from 59 to 72%), 
followed by Val/Met (from 25 to 38%) and a lower 
prevalence of the Met/Met allele (from 2 to 4%)40-42. 
The cause of PD is associated with numerous 
molecular factors linked to the survival and 
vulnerability of the dopaminergic neurons (DN) of  
the substantianigra (SN)35,43,44. In a study by  
Howells et al.45, patients with PD had low levels of 
BDNF mRNA, suggesting that low BDNF mRNA 
levels may contribute to the death of dopaminergic 
neurons and to the development of the disease. The 
regulation of BDNF expression has become a key 
strategy for the rescue of damaged dopaminergic 
neurons in PD.  
In our study, we also noted the association  
Table 7 —  Association of BDNF Val66Met polymorphism with MOCA in tremor predominant, akinetic rigidity, and mixed symptom 
cases 
Genotype Tremor dominant MoCA 
Mean ± SD (N) 
P Value Akinetic rigidity MoCA 
Mean ± SD (N) 
P Value Mixed symptom MoCA 
Mean ± SD (N) 
P Value 
GG vs GA 28.72 ± 0.23 (32) 
vs 27.77 ± 0.46 (13) 
0.050* 28.04 ± 0.18 (105) 
vs 27.42 ± 0.32 (71) 
0.0758 27.61 ± 0.60 (18) 
vs 29.13 ± 0.39 (8) 
0.1259 
GG vs AA 28.72 ± 0.23 (32) 
vs Nil 
- 28.04 ± 0.18 (105)  
vs 25.68 ± 0.44 (17) 
< 0.0001* 27.61 ± 0.60 (18) 
vs 24.40 ± 0.92 (5) 
0.0183* 
GA vs AA 27.77 ± 0.46 (13) 
vs Nil 
- 27.42 ± 0.32 (71) 
vs 25.68 ± 0.44 (17) 
0.0027* 29.13 ± 0.39 (8)  
vs 24.40 ± 0.92 (5) 
0.0002* 
GG, wild type; GA, Heterozygous; AA, mutant genotype; MoCA= Montreal cognitive assessment, *P Value ≤0.05 considered as significant. 
 
Table 8 — Association of BDNF Val66Met polymorphism with PDQ39 in tremor predominant, Akinetic rigidity and mixed symptom 
cases 
Genotype Tremor dominant PDQ 39 
Mean ± SD (N) 
P Value Akinetic rigidity PDQ 39 
Mean ± SD (N) 
P Value Mixed symptom PDQ 39 
Mean ± SD (N) 
P Value 
GG vs GA 49.63 ± 3.61 (32) 
vs 54.77 ± 6.71 (13) 
0.4718 62.33 ± 2.78 (105) 
vs 75.11 ± 5.44 (71) 
0.0373* 62.06 ± 6.54 (18) 
vs 54.00 ± 7.95 (8) 
0.4788 
GG vs AA 49.63 ± 3.61 (32) 
vs Nil 
- 62.33 ± 2.78 (105) 
vs 75.46 ± 5.00 (17) 
0.0297* 62.06 ± 6.54 (18) 
vs 79.60 ± 7.28 (5) 
0.196 
GA vs AA 54.77 ± 6.71 (13) 
vs Nil 
- 75.11 ± 5.44 (71) 
vs 75.46 ± 5.00 (17) 
0.9616 54.00 ± 7.95 (8) 
vs 79.60 ± 7.28 (5) 
0.0500* 
GG, wild type; GA, Heterozygous; AA, mutant genotype; PDQ 39= Parkinson’s disease questionnaire, *P Value ≤0.05 considered as 
significant. 
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of BDNF Val66Met polymorphism with cognitive 
impairment in PD patients. BDNF homozygous 
Met/Met genotype showed a significant higher 
frequency of cognitive impairment than Val/Val 
homozygotes. This finding is supported by  
Foltynie et al.21 in his study in 2005, where 291 
patients were investigated for the impact of BDNF 
Val66Met on cognitive impairments of the patients 
and the results of this investigation were  
the association of the BDNF polymorphism with 
planning ability in PD. A higher risk of cognitive 
impairment in PD patients was reported to be 
associated with the BDNF Val66Met allele20. 
From the epidemiological studies, it is evident that 
higher age, severe motor symptoms, older age at the 
onset, longer disease duration, and male gender  
were likely to be risk factors of PD cognitive 
dysfunction46,47. A recent study48 suggested that 
different genetic factors could play a role in cognitive 
impairment. In the experimental knockout mice 
model, it has been observed that the inhibition of 
BDNF signalling can affect spatial learning and 
memory49. Recently, it has been detected that subjects 
with BDNF Met-allele show decreased cognitive 
flexibility when compared to homozygous carriers of 
the BDNF Val-allele50. In a meta-analysis, it was 
observed that BDNF Val66Met was significantly 
associated with cognitive impairment in PD patients 
specifically in Caucasians51. In our study, there was 
no difference in gender prevalence, the age at onset, 
disease duration and the motor disability (UPDRS III 
scores) among the various alleles. The impact of the 
Met/Met genotype on cognitive impairment persisted 
after matching for the PD phenotypic subsets as well 
as the age of onset.  
In our study Met/Met genotype was not found in 
tremor predominant group and a kinetic rigidity was 
found predominant with the same genotype. Impaired 
cognition was found predominant with a kinetic 
rigidity group which was highly expressed with 
Met/Met genotype.  
The emerging evidence indicates that the BDNF 
polymorphism may modifies the clinical course of PD 
or the prevalence of PD. Our results (Cases Met/Met 
genotype frequency: 8.2 %, whereas Controls 
Met/Met genotype frequency 3.7%) were supported 
by a Japanese association study on 20 candidate gene 
SNPs and PD, revealed that the frequency of Met/Met 
genotype is higher in PD patients than healthy 
controls52. The homozygous mutant genotype 
(Met/Met: 25.48 ± 0.40) and heterozygous genotypes 
(Val/Met: 27.64 ± 0.25) were significantly associated 
with cognitive dysfunction, which was in accordance 
with two studies where the homozygous mutant 
genotype and heterozygous genotypes were shown to 
associated with higher prevalence of cognitive 
impairment in PD patients53,54. The disease severity 
was found significantly higher with Met/Met 
genotype and Val/Met genotype compared with 
Val/Val genotype53,54. In the line of with these 
findings, we also found that Met/Met genotype is 
associated with disease risk and severity. 
The clinical outcome measured as change in the 
quality of life utilising PDQ39 questioner reveals that 
Met/Met genotype was significantly associated with 
poor quality of life compared to homozygous Val 
genotype. The activity of daily living measured by 
The Schwab and England ADL (Activities of Daily 
Living) scale was significantly lower with Met/Met 
genotype. Regular follow-up of these patients in 
particularly patients carrying variant genotype may 
help in better management. 
Although our study is limited by only performing a 
screening test of cognitive impairment, we found 
irrefutable proof of the association of Met/Met 
genotype with poor cognition as well as the disease 
severity and quality of life. Therefore, given the 
importance of cognitive impairment in PD and the 
apparent influence of genetic factors in this condition, 
further prospective studies are required to explicate the 
role of genetic factors on cognitive impairment in PD. 
 
Conclusion 
We found significant association of BDNF 
Val66Met polymorphism with PD risk in both 
dominant and recessive models. Consistent with the 
literature, we also observed the cognitive impairment 
in patients carrying BDNF Val66Met polymorphism. 
In PD patients, an increase in disease severity and 
decrease in quality of life and activity of daily living 
were also observed with this polymorphism.     
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